articleThe LancetJul 23, 2008Closed access

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

RJRobert J. MotzerBEBernard EscudierSOStéphane OudardTEThomas E. HutsonCPCamillo Porta

Memorial Sloan Kettering Cancer Center · Institut Gustave Roussy · +11 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

3,010
total citations
FWCI
202.09
Percentile
100%
References
29
Citations per year

Authors

15

Topics & keywords

Topics
Keywords
  • Placebo
  • Everolimus
  • Medicine
  • Renal cell carcinoma
  • Double blind
  • Internal medicine
  • Urology
  • Oncology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding